Search
Beta Pharma Announces Breakthrough in Ensartinib Clinical Research for Postoperative Adjuvant Therapy
2025-08-25 /
Read about 0 minute
Author：小编
Beta Pharma has announced significant advancements in the clinical trials of its Ensartinib Hydrochloride Capsules for adjuvant therapy in patients with ALK-positive non-small cell lung cancer following surgery. According to a recent interim analysis of the trial, the results have been overwhelmingly positive, achieving the predefined primary endpoint with robust statistical significance and demonstrating clear clinical benefits. The company intends to present the detailed data at upcoming international academic conferences and is expediting the preparation of necessary materials to submit a New Drug Application (NDA) for this novel indication at the earliest opportunity.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
